Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study

PURPOSE: Preclinical studies suggest PARP inhibition (PARPi) induces immunostimulatory micromilieu in ovarian cancer thus complementing activity of immune checkpoint blockade. We conducted a phase 2 trial of PARPi olaparib and anti-PD-L1 durvalumab and collected paired fresh core biopsies and blood...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Lampert, Erika J., Zimmer, Alexandra, Padget, Michelle, Cimino-Mathews, Ashley, Nair, Jayakumar, Liu, Yingmiao, Swisher, Elizabeth M., Hodge, James W., Nixon, Andrew B., Nichols, Erin, Bagheri, Mohammad H., Levy, Elliott, Radke, Marc R., Lipkowitz, Stanley, Annunziata, Christina M., Taube, Janis M., Steinberg, Seth M., Lee, Jung-Min
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7442720/
https://ncbi.nlm.nih.gov/pubmed/32398324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-0056
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados